Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Blood Proteomics Complements Rare Disease Genome Sequencing

Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 10, 2026

Sentiment
5
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

This research validates the commercial potential of proteomics platforms and could accelerate investment in companies developing blood-based protein diagnostics and multi-omics tools. It may also increase demand for genomic and proteomic testing services, benefiting life sciences tools providers and diagnostics companies.

biotechnology healthcare pharmaceuticals

Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité (BIH), and United Kingdom — Genomics England have published a study in Science Translational Medicine showing that measuring proteins in the blood can provide important additional clues about the effects of genetic variants, helping to identify diagnoses and potential new disease-causing genes that genome sequencing alone has been unable to resolve. The study analyzed blood samples from people with rare diseases who remained without a genetic diagnosis following analysis through United Kingdom — Genomics England's 100,000 Genomes Project. By measuring nearly 1,500 proteins in blood and combining this information with genomic data, the researchers were able to resolve previously uncertain genetic findings and provide evidence supporting diagnoses for some patients. The approach also helped identify candidate genetic variants and genes that could potentially explain the conditions of other patients and warrant further investigation. The findings provide proof-of-principle that large-scale blood proteomics could complement genome sequencing in the diagnosis of rare disease. The team led by Claudia Langenberg, head of the BIH Computational Medicine research group and director of PHURI at Queen Mary University of London, found the approach particularly useful in patients with hereditary haemorrhagic telangiectasia (HHT), a rare inherited disorder affecting blood vessels. One example involved TIE1, a protein involved in blood vessel function, where researchers identified a rare genetic variant in a patient with a previously unexplained inherited cardiac disorder who also had exceptionally low levels of the TIE1 protein in their blood. The researchers stress that findings such as this represent candidate gene-disease links requiring further evidence rather than confirmed new causes of disease. They emphasize that further studies are needed to confirm their findings and interpretation, and that larger studies across a wider range of rare diseases and more diverse populations will now be needed.

50 United Kingdom — Genomics England identified genetic variant
govactor
Provided the 100,000 Genomes Project data and supported the study, demonstrating the value of its genomic datasets for translational research. This may enhance its profile and support for future funding.
Importance 80.0 Sentiment 8.0
per
Led the research team and is a corresponding author, playing a central role in the study design and interpretation. Her leadership adds credibility to the findings.
Importance 75.0 Sentiment 5.0
per
First author of the study, responsible for much of the analysis and interpretation. The publication boosts her academic standing.
Importance 60.0 Sentiment 5.0
per
Corresponding author who contributed to the study design and interpretation. The publication enhances his research profile.
Importance 55.0 Sentiment 5.0
per
Corresponding author from United Kingdom — Genomics England who supported the study and provided expertise in genomic data analysis. The publication strengthens his professional reputation.
Importance 50.0 Sentiment 5.0
priv
Contributed scientists and clinicians to the research collaboration. The study may enhance its visibility in the field of molecular medicine.
Importance 40.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.